KZIA
Kazia Therapeutics Limited [KZIA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KZIA Stock Summary
Top 10 Correlated ETFs
KZIA
Top 10 Correlated Stocks
KZIA
In the News
KZIA Financial details
Company Rating
Neutral
Market Cap
9.98M
Income
-39.07M
Revenue
-2.9M
Book val./share
0.06
Cash/share
0.02
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-5.5
Forward P/E
-
PEG
0.64
P/S
22176.38
P/B
9.34
P/C
18.95
P/FCF
-0.81
Quick Ratio
0.71
Current Ratio
1.42
Debt / Equity
0.15
LT Debt / Equity
-
-
-
EPS (TTM)
-0.26
EPS next Y
-
EPS next Q
-
EPS this Y
-94.09%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-42.76%
Revenue last 5Y
-18.73%
Revenue Q/Q
-
EPS Q/Q
-65.81%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
1.79%
Inst Trans
0.83%
ROA
-73%
ROE
-346%
ROC
-1.18%
Gross Margin
100%
Oper. Margin
-4342901%
Profit Margin
-3680788%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.19-1.68
52W High
-
52W Low
-
RSI
55
Rel Volume
0.31
Avg Volume
900.43K
Volume
281.27K
Perf Week
5.28%
Perf Month
82.56%
Perf Quarter
-33.51%
Perf Half Y
-42.58%
-
-
-
-
Beta
2.113
-
-
Volatility
0.03%, 0.06%
Prev Close
9.47%
Price
0.379
Change
9.92%
KZIA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.13 | 0 | 0 | |
| Net income per share | -1.79 | -1.71 | -0.07 | -1.86 | -0.11 | |
| Operating cash flow per share | -1.17 | -1.21 | -0.08 | -1.72 | -0.08 | |
| Free cash flow per share | -1.17 | -1.21 | -0.08 | -1.72 | -0.08 | |
| Cash per share | 0.94 | 1.2 | 0.23 | 0.56 | 0.03 | |
| Book value per share | 2.47 | 1.93 | 0.32 | 1.41 | 0.07 | |
| Tangible book value per share | 0.12 | 0.23 | 0.13 | -0.11 | -0.03 | |
| Share holders equity per share | 2.47 | 1.93 | 0.32 | 1.41 | 0.07 | |
| Interest debt per share | 0.38 | 0 | 0 | 0.14 | 0.01 | |
| Market cap | 21.62M | 35.82M | 1.55B | 81.61M | 319.34M | |
| Enterprise value | 16.19M | 27.05M | 1.52B | 76.09M | 315.9M | |
| P/E ratio | -2.11 | -2.87 | -184.33 | -3.31 | -15.6 | |
| Price to sales ratio | 13.82K | 33.76K | 102.25 | 3.26M | 575.39K | |
| POCF ratio | -3.22 | -4.07 | -170.4 | -3.59 | -21.07 | |
| PFCF ratio | -3.22 | -4.07 | -170.4 | -3.59 | -21.07 | |
| P/B Ratio | 1.52 | 2.54 | 41.02 | 4.38 | 26.5 | |
| PTB ratio | 1.52 | 2.54 | 41.02 | 4.38 | 26.5 | |
| EV to sales | 10.35K | 25.5K | 100.43 | 3.04M | 569.18K | |
| Enterprise value over EBITDA | -2.22 | -2.36 | -298.24 | -3.08 | -14.18 | |
| EV to operating cash flow | -2.41 | -3.07 | -167.38 | -3.34 | -20.84 | |
| EV to free cash flow | -2.41 | -3.07 | -167.38 | -3.34 | -20.84 | |
| Earnings yield | -0.47 | -0.35 | -0.01 | -0.3 | -0.06 | |
| Free cash flow yield | -0.31 | -0.25 | -0.01 | -0.28 | -0.05 | |
| Debt to equity | 0 | 0 | 0 | 0.1 | 0.15 | |
| Debt to assets | 0 | 0 | 0 | 0.05 | 0.06 | |
| Net debt to EBITDA | 0.74 | 0.77 | 5.4 | 0.22 | 0.15 | |
| Current ratio | 3.96 | 2.1 | 3.53 | 1.62 | 1.42 | |
| Interest coverage | -3.83 | 0 | 0 | -12.75K | 0 | |
| Income quality | 0.65 | 0.71 | 1.08 | 0.92 | 0.74 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.42K | 3.48K | 0.46 | 180.46K | 15.46K | |
| Research and developement to revenue | 4.14K | 8.95K | 0.96 | 810.09K | 28.04K | |
| Intangibles to total assets | 0.64 | 0.54 | 0.38 | 0.57 | 0.61 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 157.19 | 246.94 | 0.04 | 67K | 2.09K | |
| Graham number | 9.96 | 8.62 | 0.72 | 7.67 | 0.41 | |
| ROIC | -0.57 | -0.87 | -0.18 | -1.28 | -1.77 | |
| Return on tangible assets | -1.34 | -1.17 | -0.23 | -1.65 | -1.89 | |
| Graham Net | -0.2 | 0.1 | 0.06 | -0.67 | -0.06 | |
| Working capital | 5.62M | 5.59M | 21.06M | 2.92M | 3.21M | |
| Tangible asset value | 701K | 1.72M | 15.85M | -1.41M | -5.22M | |
| Net current asset value | 533K | 1.72M | 9.15M | -8.71M | -5.26M | |
| Invested capital | 0 | 0 | 0 | 0.1 | 0.15 | |
| Average receivables | 1.94M | 1.37M | 639K | 67.68K | 25.98K | |
| Average payables | 1.23M | 1.37M | 1.79M | 1.71M | 1.19M | |
| Average inventory | -776K | -776K | -42K | -42K | 0 | |
| Days sales outstanding | 361.97K | 410.75K | 2.02 | 749.75K | 401.17 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 180.75 | 0 | 0.91 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.72 | -0.88 | -0.22 | -1.32 | -1.7 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q4
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | -0.02 | 0 | 0 | 0 | |
| Net income per share | -0.04 | -0.09 | -0.05 | -0.09 | -0.03 | |
| Operating cash flow per share | -0.04 | -0.09 | -0.03 | -0.06 | -0.03 | |
| Free cash flow per share | -0.04 | -0.09 | -0.03 | -0.06 | -0.03 | |
| Cash per share | 0.06 | 0.06 | 0 | 0.03 | 0.02 | |
| Book value per share | 0.12 | 0.14 | 0 | 0.08 | 0.06 | |
| Tangible book value per share | 0.08 | -0.01 | 0 | -0.05 | -0.02 | |
| Share holders equity per share | 0.12 | 0.14 | 0 | 0.08 | 0.06 | |
| Interest debt per share | 0 | 0.03 | 0 | 0 | 0.01 | |
| Market cap | 1.37B | 558.27M | 160.23M | 130.36M | 377.97M | |
| Enterprise value | 1.36B | 550.91M | 160.23M | 126.52M | 374.53M | |
| P/E ratio | -57.83 | -11.82 | -5.9 | -2.4 | -13.74 | |
| Price to sales ratio | 0 | -192.62 | 0 | 0 | 681.03K | |
| POCF ratio | -240.31 | -49.09 | -36.39 | -14.8 | -59.52 | |
| PFCF ratio | -240.31 | -49.09 | -36.39 | -14.8 | -59.52 | |
| P/B Ratio | 86.13 | 30.55 | 0 | 11.25 | 31.37 | |
| PTB ratio | 86.13 | 30.55 | 0 | 11.25 | 31.37 | |
| EV to sales | 0 | -190.08 | 0 | 0 | 674.82K | |
| Enterprise value over EBITDA | -246.99 | -50.07 | -25.23 | -9.96 | -39.11 | |
| EV to operating cash flow | -239.01 | -48.45 | -36.39 | -14.37 | -58.98 | |
| EV to free cash flow | -239.01 | -48.45 | -36.39 | -14.37 | -58.98 | |
| Earnings yield | 0 | -0.02 | -0.04 | -0.1 | -0.02 | |
| Free cash flow yield | 0 | -0.02 | -0.03 | -0.07 | -0.02 | |
| Debt to equity | 0 | 0 | 0 | 0.05 | 0.15 | |
| Debt to assets | 0 | 0 | 0 | 0.02 | 0.06 | |
| Net debt to EBITDA | 1.34 | 0.67 | 0 | 0.3 | 0.36 | |
| Current ratio | 1.4 | 1.4 | 0 | 1.06 | 1.42 | |
| Interest coverage | 0 | -2.69 | 0 | 0 | 0 | |
| Income quality | 0.96 | 0.96 | 0.65 | 0.65 | 0.92 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | -0.91 | 0 | 0 | 7.76K | |
| Research and developement to revenue | 0 | -3.17 | 0 | 0 | 11.18K | |
| Intangibles to total assets | 0.53 | 0.53 | 0 | 0.65 | 0.61 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | -0.36 | 0 | 0 | 386.3 | |
| Graham number | 0.35 | 0.52 | 0 | 0.41 | 0.2 | |
| ROIC | -0.38 | -0.66 | 0 | -1.13 | -0.77 | |
| Return on tangible assets | -0.35 | -0.71 | 0 | -1.41 | -0.64 | |
| Graham Net | 0 | -0.08 | 0 | -0.08 | -0.05 | |
| Working capital | 2.72M | 2.72M | 0 | 333.83K | 3.21M | |
| Tangible asset value | 10.02M | -864.37K | 0 | -6.62M | -5.22M | |
| Net current asset value | 2.72M | -8.17M | 0 | -10.34M | -5.26M | |
| Invested capital | 0 | 0 | 0 | 0.05 | 0.15 | |
| Average receivables | 34.01K | 0 | 0 | 350.48K | 0 | |
| Average payables | 1.94M | 1.52M | 762.09K | 1.15M | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 17.13K | |
| Days payables outstanding | 0 | 47.33 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0.01 | |
| Payables turnover | 0 | 1.9 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.37 | -0.65 | 0 | -1.17 | -0.57 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
KZIA Frequently Asked Questions
What is Kazia Therapeutics Limited stock symbol ?
Kazia Therapeutics Limited is a AU stock , located in Sydney of Nsw and trading under the symbol KZIA
What is Kazia Therapeutics Limited stock quote today ?
Kazia Therapeutics Limited stock price is $0.379 today.
Is Kazia Therapeutics Limited stock public?
Yes, Kazia Therapeutics Limited is a publicly traded company.
Company Profile
- Volume Average 900.43K
- Market Capitalization 9.98M
- Employee 9
- CEO Dr. John Edwin Friend II, M.D.
- Headquarters Sydney,NSW,AU
- IPO Date 1999-01-06
-
Website
https://www.kaziatherapeutics.com 
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
